Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Efficacy and safety of infliximab for the treatment of psoriatic arthritis

Nature Clinical Practice Rheumatology volume 2, pages 300–301 (2006)Cite this article

boxed-textAntoni C et al. (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64: 1150–1157

Infliximab can be used to treat arthritis, dactylitis, enthesitis, and skin disease in patients with psoriatic arthritis

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Antoni C et al. (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52: 2951

    Article  CAS  Google Scholar 

  2. Ritchlin C (2006) Newer therapeutic approaches: spondyloarthritis and uveitis. Rheum Dis Clin North Am 32: 75–90

    Article  Google Scholar 

  3. Maini R et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group. Lancet 354: 1932–1939

    Article  CAS  Google Scholar 

  4. Klareskog L et al. (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675–681

    Article  CAS  Google Scholar 

  5. Kavanaugh A et al. (2006) The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis [doi: ard.2005.045658v2]

Download references

Acknowledgements

The Synopsis was written by Christopher Ritchlin.

Author information

Authors and Affiliations

  1. an Associate Professor of Medicine of the University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

    Christopher Ritchlin

Authors
  1. Christopher Ritchlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher Ritchlin.

Ethics declarations

Competing interests

C Ritchlin provides research support for Centocor and is a Consultant for Abbott, Centocor, Wyeth, and Biogen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ritchlin, C. Efficacy and safety of infliximab for the treatment of psoriatic arthritis. Nat Rev Rheumatol 2, 300–301 (2006). https://doi.org/10.1038/ncprheum0209

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0209

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing